November 13, 2016
Please join us in congratulating Dr. Mark Rubin on receiving a 3-year R01 award for $500k.
Along with his collaborator at Yale, Dr. Mark Gerstein, Dr. Rubin will develop approaches to identify non-coding mutations that are important for prostate cancer.
Mark A Rubin, MD Director, Institute for Precision Medicine
Cancer cells have many non-coding mutations. The significance of these potential important mutations to disease is unknown and has been largely unexplored. Dr. Rubin will develop approaches to identify non-coding mutations that likely contribute to prostate cancer and determine how these mutations impact the expression of genes required for this disease.
Congratulations Dr. Rubin!